Tacrolimus and quality of life after kidney transplantation - a multicenter study

Página do item simplificado
dc.contributor.authorBohlke, M.
dc.contributor.authorRocha, M.
dc.contributor.authorGomes, R. H.
dc.contributor.authorMarini, S. S.
dc.contributor.authorTerhorst, L.
dc.contributor.authorBarcellos, F. C.
dc.contributor.authorHallal, P. C.
dc.contributor.authorCasarini, D.
dc.contributor.authorIrigoyen, M. C.
dc.contributor.institutionCatholic Univ Pelotas
dc.contributor.institutionFed Univ Pelotas
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.date.accessioned2016-01-24T12:41:20Z
dc.date.available2016-01-24T12:41:20Z
dc.date.issued2006-07-01
dc.description.abstractKidney transplantation is currently the treatment of choice for end-stage renal disease. Although new immunosuppressive drugs have been introduced into clinical practice, the effect of such medication on quality of life (QoL) in transplant recipients is still unclear. the present study analyzes the impact of tacrolimus-based immunosuppression on QoL in a representative sample of adult kidney transplant recipients from Rio Grande do Sul, a Brazilian southern state. This was a cross-sectional multicenter study which used the SF-36 Health Survey for measuring QoL. the effect of tacrolimus on QoL was adjusted for possible confounders using multiple linear regression. A total of 272 patients (from 11 different centers) were evaluated, 48 of them were treated with tacrolimus. Transplant patients in use of tacrolimus presented significant higher scores in the physical component summary of SF-36 than non-users (49.1 +/- 8.3 vs. 46.1 +/- 8.7; p = 0.03), and such difference was noted in the physical functioning and general health subscales (81.5 +/- 17.1 and 74.7 +/- 21.8; 74.6 +/- 22.3 and 67.1 +/- 22.3 for users and non-users of tacrolimus, respectively, p < 0.05). the effect of tacrolimus remained significant after adjustment for age, gender, skin color and time since transplantation (coeff.: 2.83; 95% CI: 0.05-5.6, p = 0.045). the association between tacrolimus-based immunosuppression and better perception of physical functioning and general health for renal transplant patients represents a significant finding as it may influence therapeutical decisions and contribute to maximize kidney transplantation benefits.en
dc.description.affiliationCatholic Univ Pelotas, Sch Med, Pelotas, Brazil
dc.description.affiliationFed Univ Pelotas, Postgrad Program Epidemiol, Pelotas, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Postgrad Program Nephrol, São Paulo, Brazil
dc.description.affiliationFMUSP, INCOR, Hypertens Unit, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Postgrad Program Nephrol, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent504-508
dc.identifierhttp://dx.doi.org/10.1111/j.1399-0012.2006.00513.x
dc.identifier.citationClinical Transplantation. Oxford: Blackwell Publishing, v. 20, n. 4, p. 504-508, 2006.
dc.identifier.doi10.1111/j.1399-0012.2006.00513.x
dc.identifier.issn0902-0063
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/29041
dc.identifier.wosWOS:000238743900017
dc.language.isoeng
dc.publisherBlackwell Publishing
dc.relation.ispartofClinical Transplantation
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectimmunosuppressionen
dc.subjectkidney transplantationen
dc.subjectquality of lifeen
dc.subjecttacrolimusen
dc.titleTacrolimus and quality of life after kidney transplantation - a multicenter studyen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos